Press Releases

Date Title and Summary View
Toggle Summary Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
VANCOUVER, British Columbia , May 10, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Presentation of LEADERSHIP 201 Results at Upcoming American Urological Association Annual Meeting
Phase II Results Accepted for Publication in Journal of Urology VANCOUVER, British Columbia , May 05, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of
View HTML
Toggle Summary Aquinox to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia , April 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox to Present at 2016 Annual Needham Healthcare Conference
VANCOUVER, British Columbia , April 06, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Year End 2015 Financial Results
Advancing to first Phase 3 trial for AQX-1125 in IC/BPS Host conference call update today at 4:30PM ET VANCOUVER, British Columbia , March 14, 2016 (GLOBE NEWSWIRE) --   Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing
View HTML
Toggle Summary Aquinox Pharmaceuticals to Announce Year End 2015 Financial Results
VANCOUVER, British Columbia , March 08, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its year end 2015
View HTML
Toggle Summary Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference
VANCOUVER, British Columbia , Jan. 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
VANCOUVER, British Columbia , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced receipt of
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
VANCOUVER, British Columbia, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the
View HTML
Toggle Summary Aquinox Selected for Addition to NASDAQ Biotechnology Index
VANCOUVER, British Columbia, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it has been
View HTML